All In Biotech

BLA 125387 · Regeneron Pharmaceuticals

Eylea

Aflibercept · Injection · Vascular Endothelial Growth Factor Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Nov 18, 2011

Approved uses

8

Original approval plus efficacy supplements

Registered trials

474

135 Phase 3, 39 recruiting

FAERS reports

30,249

24,786 serious, 8,878 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 7, 2026.

EYLEA is indicated for the treatment of: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Retinopathy of Prematurity (ROP) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Retinopathy of Prematurity (ROP)

Mechanism: Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 8, 2023 Supplement 75 · Efficacy · priority review OrphanLetterLabel
  • May 13, 2019 Supplement 61 · Efficacy LabelLetterReview
  • Aug 16, 2018 Supplement 56 · Efficacy LabelLetter
  • Mar 25, 2015 Supplement 48 · Efficacy · priority review Breakthrough therapyReviewLetterLabel
  • Oct 6, 2014 Supplement 43 · Efficacy LabelLetter
  • Jul 29, 2014 Supplement 37 · Efficacy Letter
  • Sep 21, 2012 Supplement 4 · Efficacy LabelLetter
  • Nov 18, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • EYLEA · AFLIBERCEPT 40MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aflibercept" as an intervention, any sponsor and status, largest first.

All 474 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death7,876
  • visual impairment2,037
  • off label use1,631
  • blindness1,437
  • endophthalmitis1,341
  • visual acuity reduced1,236
  • drug ineffective1,188
  • eye pain1,162
  • vision blurred1,149
  • product dose omission issue1,106
  • blindness unilateral1,048
  • blindness transient977

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20075
20082
200911
201045
201127
2012172
2013575
2014852
20151,499
20162,240
20172,841
20184,387
20194,417
20203,536
20211,917
20221,690
20231,473
20242,271
20251,098
20261,191

Recalls

2 FDA enforcement reports for this application.

  • May 15, 2024 · Class II · Terminated

    Lack of Assurance of Sterility: Complaints of syringe breakage

  • Apr 23, 2024 · Class II · Terminated

    Lack of Assurance of Sterility: Complaints of syringe breakage

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Eylea (Aflibercept)

2024 spending

$71.1M

Beneficiaries

7,368

29,232 claims

Per beneficiary

$9,656

$37,751.23 per unit

View as table
YearSpending
2020$25,587,701
2021$31,166,271
2022$68,312,404
2023$73,869,613
2024$71,144,895

Part B: Eylea (Aflibercept) · HCPCS J0178

2024 spending

$2.37B

Beneficiaries

293,280

1,233,027 claims

Per beneficiary

$8,065

2024 ASP limit $840.20 per unit

View as table
YearSpending
2020$3,013,346,116
2021$3,415,890,772
2022$3,541,909,704
2023$3,148,337,301
2024$2,365,369,089

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 642 on PubMed

Sponsor: Regeneron

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.